Basic Information
| LncRNA/CircRNA Name | PCAT1 |
| Synonyms | LPCAT1, AGPAT10, AGPAT9, AYTL2, LPCAT-1, PFAAP3, lpcat, lysoPAFAT, PCAT-1 |
| Region | GRCh38_8:126556323-127419050 |
| Ensemble | ENSG00000253438 |
| Refseq | NR_045262 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin (DDP) | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Luciferase reporter assay, Western blot |
| Sample | Human fetal gastric epithelial cell line (GES-1) and human GC cell lines (BGC823 and SGC7901), Tumor (n = 38) and adjacent normal (n = 38) tissues |
| Expression Pattern | up-regulated |
| Function Description | PCAT-1 was up-regulated in DDP-resistant GC tissues and cells. GC patients with high PCAT-1 expression levels had a poor prognosis. Knockdown of PCAT-1 facilitated the sensitivity of DDPresistant GC cells to DDP. Additionally, PCAT-1 functioned as a sponge of miR-128 in GC cells. Moreover, inhibition of miR-128 reversed the inductive effect of PCAT-1 knockdown on DDP sensitivity of GC cells. In addition, ZEB1 was identified as a target of miR-128, and overexpression of ZEB1 could block the inductive effect of PCAT-1 knockdown on DDP sensitivity of GC cells. Besides, PCAT-1 knockdown enhanced DDP sensitivity in tumors in vivo. |
| Pubmed ID | 31352238 |
| Year | 2019 |
| Title | PCAT-1 contributes to cisplatin resistance in gastric cancer through miR128/ZEB1 axis |
External Links
| Links for PCAT1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |